Immune System Diseases: Clinical Trials

27002 completed, 5660 unknown, 5130 recruiting, 3709 terminated. 12368 Phase 2, 10191 Not applicable, 8808 Phase 1, 5595 Phase 3, 2865 Phase 4.

By phase and status

Phase	Trials	Status
Phase 2	12368	Completed 6540, Terminated 1529, Recruiting 1400, Unknown 1122, Active not recruiting 755, Withdrawn 553, Not yet recruiting 395, Enrolling by invitation 39, Suspended 35
Not applicable	10191	Completed 5969, Unknown 1440, Recruiting 1082, Not yet recruiting 501, Terminated 459, Active not recruiting 366, Withdrawn 250, Enrolling by invitation 89, Suspended 35
Phase 1	8808	Completed 4919, Terminated 1053, Recruiting 966, Unknown 696, Active not recruiting 476, Withdrawn 379, Not yet recruiting 259, Suspended 36, Enrolling by invitation 24
Phase 3	5595	Completed 3607, Unknown 463, Recruiting 443, Terminated 431, Active not recruiting 329, Withdrawn 171, Not yet recruiting 124, Enrolling by invitation 20, Suspended 7
Phase 4	2865	Completed 1788, Unknown 411, Terminated 243, Recruiting 179, Withdrawn 93, Not yet recruiting 76, Active not recruiting 64, Enrolling by invitation 10, Suspended 1
Early Phase 1	633	Completed 177, Recruiting 131, Unknown 118, Not yet recruiting 79, Terminated 50, Withdrawn 31, Active not recruiting 30, Suspended 10, Enrolling by invitation 7

Follow Immune System Diseases: new trials by email Literature Review of Immune System Diseases trials Research Report on Immune System Diseases

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

Trial	Phase	Status	Sponsor	Enrollment	Start	Updated
Effect of S. Aureus Skin Decolonization on Disease Severity in Atopic Dermatitis Patients Skin Cleanser Combination No.1 - Atopic Dermatitis	Phase 4	Not yet recruiting	Boston Children's Hospital	100	2031-01-01	2026-03-10
Open-label Pilot Clinical Trial of Oral Ivermectin to Treat Atopic Dermatitis Ivermectin Pill - Atopic Dermatitis	Phase 2	Withdrawn	Stanford University		2030-12-01	2024-12-02
Outcomes in Stevens Johnsons Syndrome and Toxic Epidermal Necrolysis Site specific standard of care comparison - Stevens-Johnson Syndrome, Toxic Epidermal Necrolysis		Withdrawn	Massachusetts General Hospital		2030-01-01	2026-01-16
Comparison of Vigorous Versus Low Intensity Cool Room Treadmill Training in People with Multiple Sclerosis Body-weight supported treadmill training in a room cooled to 16°C - Multiple Sclerosis, Neurological Rehabilitation	Not applicable	Withdrawn	Memorial University of Newfoundland		2030-01-01	2024-11-27
FLASH Pilot Phase 1 Safety Study IntraOp Mobetron UHDR, Linac - Cutaneous Lymphoma	Not applicable	Not yet recruiting	Lesley A. Jarvis	10	2029-10-31	2026-05-27
Evaluating a Clinical Decision Support Tool for Antiretroviral Therapy Optimization smART (Smart Antiretroviral Therapy Assistant), Traditional Prescribing resources - HIV (Human Immunodeficiency Virus), Clinical Decision Support System (CDSS)	Not applicable	Not yet recruiting	Keck School of Medicine of USC	250	2028-09-01	2025-10-22
Cannabichromene Safety in Rheumatoid Arthritis Cannabichromene - Arthritis, Rheumatoid	Phase 1 / Phase 2	Withdrawn	Crystal Lederhos Smith		2028-07-15	2026-09-23
EFFECT OF AYURVEDA TREATMENT IN ALLERGIC RHINITIS AYURVEDA treatment protocol, Control(Citrizine 10mg) - Allergic Rhinitis (AR)	Not applicable	Not yet recruiting	Amrita Vishwa Vidyapeetham	104	2028-06-30	2026-06-04
A Study Evaluating Subcutaneous Versus Intravenous Blinatumomab in Newly Diagnosed Adults With B-cell Precursor Acute Lymphoblastic Leukaemia Blinatumomab, HyperCVAD - Philadelphia Chromosome Negative B-cell Precursor Acute Lymphoblastic Leukemia	Phase 3	Not yet recruiting	Amgen	560	2028-06-30	2026-09-15
Pyronaridine in Acute Myeloid Leukemia (AML) Pyronaridine Tetraphosphate - Acute Myeloid Leukemia (AML), Acute Lymphoblastic Leukemia (ALL)	Phase 2	Suspended	Armaceutica, Inc.	200	2028-02-21	2026-10-19
MM-CARE: Cardiovascular Risk Assessment in Adults With Multiple Myeloma Oncology-Embedded Cardiovascular Risk Assessment Pathway, Primary Care Provider-Directed Cardiovascular Risk Assessment Pathway - Multiple Myeloma, Heart Disease Risk Factors	Not applicable	Not yet recruiting	University of Vermont Medical Center	33	2028-02-01	2026-08-25
Study of NM8074 in Patients With Immunoglobulin A Nephropathy (IgAN) NM8074 - IgA Nephropathy	Phase 2	Not yet recruiting	NovelMed Therapeutics	10	2028-02-01	2026-04-13
Insul-In This Together: Leveraging Family Support and Diabetes Technology for Adolescents Living With Type 1 Diabetes Insul-In This Together - Diabetes Type 1	Not applicable	Not yet recruiting	Stanford University	200	2028-01-01	2026-10-05
Social Contact-Based Brief Video Interventions To Reduce Stigma and ImproVe Engagement in HIV Prevention and Care and Mental Health Care for Youth Living With and Vulnerable to HIV Brief Videos for HIV Stigma - HIV, Mental Health	Not applicable	Not yet recruiting	City University of New York, School of Public Health	3900	2028-01-01	2026-10-01
An Open-label Study of GC012F in Rheumatoid Arthritis. LD and GC012F CAR-T Cell Injection, GC012F CAR-T Cell Injection - Rheumatoid Arthritis	Early Phase 1	Withdrawn	Institute of Hematology & Blood Diseases Hospital, China		2027-12-01	2026-06-10
CRISPR-Edited Allogeneic Anti-CD19 CAR-T Cell Therapy, in Patients With Refractory Systemic Lupus Erythematosus (GALLOP) CB-010 - Systemic Lupus Erythematosus, Lupus	Phase 1	Withdrawn	Caribou Biosciences, Inc.		2027-12-01	2025-09-19
Study of YKST02 in Adults With Relapsed or Refractory Multiple Myeloma YKST02 - Relapsed or Refractory Multiple Myeloma (RRMM)	Phase 2	Not yet recruiting	Excyte Biopharma Ltd	64	2027-12-01	2026-11-06
Blood Biomarkers for Prognostic Stratification in Guillain-Barré Syndrome Blood Biomarker Panel Assessment (EGR1, EGR2, GBP1, miR-29c, and Piccolo) - Guillain Barré Syndrome		Recruiting	Anahuac University	140	2027-12-01	2026-11-13
Same-Day Antiretroviral Therapy as a Behavioral Design Intervention to Reduce Stigma in Key Affected Populations SD-ART - Hiv	Not applicable	Not yet recruiting	Yale University	139	2027-10-01	2026-08-31
Inductive Therapeutic Exercise in Multiple Sclerosis Experimental: Inductive Therapeutic Exercise (ETI), Control: Sham Inductive Therapeutic Exercise (sham-ETI) - Multiple Sclerosis	Not applicable	Not yet recruiting	Fundación San Juan De Dios	30	2027-10-01	2026-10-02

Showing 20 of 47592. Sign in to see all of them.

Narrower conditions

HIV Infections (4680)  ·  Asthma (4474)  ·  Multiple Myeloma (3675)  ·  Diabetes Mellitus, Type 1 (3573)  ·  Arthritis, Rheumatoid (3290)  ·  Multiple Sclerosis (3165)  ·  Acquired Immunodeficiency Syndrome (3037)  ·  Lymphoma (3018)  ·  Precursor Cell Lymphoblastic Leukemia-Lymphoma (2522)  ·  Lymphoma, Non-Hodgkin (2287)  ·  Leukemia, Lymphocytic, Chronic, B-Cell (2018)  ·  Lymphoma, Follicular (1875)  ·  Lymphoma, Large B-Cell, Diffuse (1831)  ·  Dermatitis, Atopic (1522)  ·  Leukemia (1441)

Broader conditions

Hemic and Lymphatic Diseases (16001)  ·  Autoimmune Diseases (14530)  ·  Neoplasms (14327)  ·  Lymphoproliferative Disorders (14297)  ·  Neoplasms by Histologic Type (14297)  ·  Immunoproliferative Disorders (14193)  ·  Lymphatic Diseases (11541)  ·  Hematologic Diseases (9762)  ·  Pathological Conditions, Signs and Symptoms (9449)  ·  Infections (8718)  ·  Skin and Connective Tissue Diseases (8630)  ·  Hypersensitivity (8559)  ·  Hypersensitivity, Immediate (8497)  ·  Urogenital Diseases (8368)

Interventions

Cyclophosphamide (1792)  ·  Rituximab (1770)  ·  Dexamethasone (1362)  ·  Methotrexate (834)  ·  Prednisone (832)  ·  Lenalidomide (830)  ·  Vincristine (708)  ·  Bortezomib (693)  ·  Doxorubicin (650)  ·  fludarabine (645)  ·  Etoposide (553)  ·  Cytarabine (527)  ·  Melphalan (474)  ·  fludarabine phosphate (474)  ·  Filgrastim (457)

Sponsors

National Institute of Allergy and Infectious Diseases (NIAID) (1365)  ·  National Cancer Institute (NCI) (714)  ·  GlaxoSmithKline (634)  ·  Novartis Pharmaceuticals (536)  ·  AstraZeneca (523)  ·  Hoffmann-La Roche (509)  ·  M.D. Anderson Cancer Center (489)  ·  Pfizer (374)  ·  Assistance Publique - Hôpitaux de Paris (341)  ·  Sanofi (291)  ·  Bristol-Myers Squibb (282)  ·  Memorial Sloan Kettering Cancer Center (281)  ·  University of California, San Francisco (271)  ·  Mayo Clinic (268)  ·  Assiut University (267)

Countries

United States (20607)  ·  France (4402)  ·  China (4374)  ·  Germany (3683)  ·  Canada (3508)  ·  United Kingdom (3468)  ·  Italy (3081)  ·  Spain (3058)  ·  Poland (2014)  ·  Australia (1838)  ·  Belgium (1675)  ·  Netherlands (1557)  ·  South Korea (1368)  ·  Japan (1310)  ·  Turkey (Türkiye) (1272)

Results publications

PMID 34515338, PMID 33687069, PMID 41671463, PMID 36472162, PMID 38299639, PMID 32816215, PMID 36600185, PMID 36601090, PMID 36931693, PMID 35622074, PMID 36526796, PMID 33127856, PMID 34870800, PMID 40135712, PMID 28143815, PMID 32632956, PMID 32499241, PMID 39192350, PMID 25047021, PMID 27338778, PMID 34778952, PMID 36326435, PMID 27881132, PMID 38958913, PMID 32779730, PMID 40190112, PMID 29244149, PMID 30649524, PMID 34398557, PMID 37453736, PMID 25820067, PMID 39324693, PMID 39735417, PMID 26275429, PMID 31401903, PMID 33263165, PMID 33305842, PMID 34706874, PMID 35636689, PMID 36754548, PMID 37528520, PMID 39393433, PMID 39588375, PMID 40465397, PMID 40550489, PMID 40875187, PMID 29463520, PMID 31319851, PMID 33006765, PMID 33357481

NIH funding

2023 (352), 2015 (221), 2018 (219), 2017 (208), 2014 (202), 2016 (200), 2019 (187), 2009 (182), 2025 (181), 2008 (128), P30CA033572 (114), P30CA015704 (100), P30CA015083 (77), 2005 (73), U10CA032102 (62)